
Atenção:
O eduCAPES é um repositório de objetos educacionais, não sendo responsável por materiais de terceiros submetidos na plataforma. O usuário assume ampla e total responsabilidade quanto à originalidade, à titularidade e ao conteúdo, citações de obras consultadas, referências e outros elementos que fazem parte do material que deseja submeter. Recomendamos que se reporte diretamente ao(s) autor(es), indicando qual parte do material foi considerada imprópria (cite página e parágrafo) e justificando sua denúncia.
Caso seja o autor original de algum material publicado indevidamente ou sem autorização, será necessário que se identifique informando nome completo, CPF e data de nascimento. Caso possua uma decisão judicial para retirada do material, solicitamos que informe o link de acesso ao documento, bem como quaisquer dados necessários ao acesso, no campo abaixo.
Todas as denúncias são sigilosas e sua identidade será preservada. Os campos nome e e-mail são de preenchimento opcional. Porém, ao deixar de informar seu e-mail, um possível retorno será inviabilizado e/ou sua denúncia poderá ser desconsiderada no caso de necessitar de informações complementares.
| Metadados | Descrição | Idioma |
|---|---|---|
| Autor(es): dc.creator | Zhong, Han | - |
| Autor(es): dc.creator | Wang, Yan | - |
| Autor(es): dc.creator | Zhang, Zai-Li | - |
| Autor(es): dc.creator | Liu, Yang-Xi | - |
| Autor(es): dc.creator | Le, Ke-Jia | - |
| Autor(es): dc.creator | Cui, Min | - |
| Autor(es): dc.creator | Yu, Yue-Tian | - |
| Autor(es): dc.creator | Gu, Zhi-Chun | - |
| Autor(es): dc.creator | Gao, Yuan | - |
| Autor(es): dc.creator | Lin, Hou-Wen | - |
| Data de aceite: dc.date.accessioned | 2026-02-09T12:09:40Z | - |
| Data de disponibilização: dc.date.available | 2026-02-09T12:09:40Z | - |
| Data de envio: dc.date.issued | 2020-05-27 | - |
| Data de envio: dc.date.issued | 2020-05-27 | - |
| Data de envio: dc.date.issued | 2019 | - |
| Fonte completa do material: dc.identifier | https://repositorio.ufla.br/handle/1/41251 | - |
| Fonte completa do material: dc.identifier | https://www.sciencedirect.com/science/article/abs/pii/S1043661820311804 | - |
| Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/1155622 | - |
| Descrição: dc.description | The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I2 = 81.3%), remarkably ameliorate clinical improvement (RR 1.52, 95% CI 1.05-2.19) and radiographical improvement (RR 1.62, 95% CI 1.11-2.36, I 2 = 11.0 %), without manifesting clear effect on virological eradication, incidence of ARDS, intubation, and AEs. Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). The lopinavir/ritonavir-based combination showed superior virological eradication and radiographical improvement with reduced rate of ARDS. Likewise, hydroxychloroquine improved radiographical result. For safety, ribavirin could induce more bradycardia, anemia and transaminitis. Meanwhile, hydroxychloroquine could increase AEs rate especially diarrhea. Overall, the quality of evidence on most outcomes were very low. In conclusion, although we could not draw a clear conclusion for the recommendation of potential therapies for COVID-19 considering the very low quality of evidence and wide heterogeneity of interventions and indications, our results may help clinicians to comprehensively understand the advantages and drawbacks of each anti-coronavirus agents on efficacy and safety profiles. Lopinavir/ritonavir combinations might observe better virological eradication capability than other anti-coronavirus agents. Conversely, ribavirin might cause more safety concerns especially bradycardia. Thus, large RCTs objectively assessing the efficacy of antiviral therapies for SARS-CoV-2 infections should be conducted with high priority. | - |
| Idioma: dc.language | en | - |
| Publicador: dc.publisher | Elsevier | - |
| Direitos: dc.rights | restrictAccess | - |
| ???dc.source???: dc.source | Pharmacological Research | - |
| Palavras-chave: dc.subject | COVID-19 | - |
| Palavras-chave: dc.subject | Severe Acute Respiratory Syndrome (SARS) | - |
| Palavras-chave: dc.subject | Middle Eastern Respiratory Syndrome (MERS) | - |
| Palavras-chave: dc.subject | Therapeutic options - Efficacy | - |
| Palavras-chave: dc.subject | Therapeutic options - Safety | - |
| Título: dc.title | Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis | - |
| Tipo de arquivo: dc.type | Artigo | - |
| Aparece nas coleções: | Repositório Institucional da Universidade Federal de Lavras (RIUFLA) | |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: